James Rubenstein

Credentials: · · · ·

History

Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma
National Cancer Institute · R01
Contact PI · $3.1M · University of California, San Francisco
2019–2025
Recognition and Targeting of CNS Lymphoma by Tumor-Associated Macrophages
National Cancer Institute · R01
Contact PI · $3.4M · University of California, San Francisco
2009–2020
Targeted Therapies in CNS Lymphomas
National Cancer Institute · R21
Contact PI · $378.2K · University of California, San Francisco
2014–2016
Molecular Classification and Therapy of CNS Lymphomas
National Cancer Institute · K23
Contact PI · $635.1K · University of California, San Francisco
2004–2009

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Principal investigator · Recruiting · Phase 1, Phase 2
James Rubenstein
2022–2027
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
Principal investigator · Recruiting · Phase 1
James Rubenstein
2021–2027
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Principal investigator · Completed · Phase 1
James Rubenstein
2012–2016
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
Principal investigator · Withdrawn · Phase 1
University of California, San Francisco
2009